Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Bumble Inc (BMBL) Price & Performance

Abeona Therapeutics IncTrade
Bumble IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Bumble Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Bumble Inc trades at $2.64 (market cap $366.87M). The key difference: Abeona Therapeutics Inc and Bumble Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

ABEOBMBL
Market Cap
$421.19M$366.87M
Sector
HealthTechnology
52-Week High
$7.45$7.17
52-Week Low
$4.17$2.70
Enterprise Value
$276.10M$672.73M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Bumble Inc

Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.

The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL